Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Analysts See Daiichi Weathering Ranbaxy Merger Fallout

This article was originally published in PharmAsia News

Executive Summary

Daiichi Sankyo's beginnings as the parent of Ranbaxy Laboratories of India is costing the Japanese firm in the short run, but the deal still is expected to be beneficial in the long run, according to analysts. Since acquiring Ranbaxy, Daiichi has seen its shares under pressure because of problems with two of the Indian drug maker's factories that led to a temporary U.S. ban on its products. Analysts expect Daiichi to weather the fallout and become more stable with Ranbaxy as a subsidiary. (Click here for more - a subscription may be required

You may also be interested in...



Ironwood Ends Phase III GERD Program, Will Cut 100 Jobs

The company has no development programs left in its R&D pipeline and will focus entirely on the commercialization of IBS drug Linzess while seeking late-stage assets from external sources.

FDA Finalizes Guidance On Blood Glucose Meters With Separate Documents For OTC, Rx Devices

The documents issued by the US agency on 29 September set slightly different accuracy standards, reflecting the increased fragility of hospital patients.

Hahn Praises CDRH Staff For Mitigating COVID-19 Deaths

The US FDA commissioner published a blog post commending and highlighting the work device center staff have done during the pandemic to speed tests and devices to market to save lives.

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel